Patient Phenotypes Within the Clinical Program of an IL-23 Inhibitor for PsA

Save

Watch rheumatologist Dr. Alexis Ogdie and rheumatologist and dermatologist Dr. Saakshi Khattri discuss a new analysis of patient phenotypes in PsA from clinical trials of an IL-23 inhibitor. In this conversation, they discuss disease activity differences between clinical trial populations and real-world patients, efficacy of an IL-23 inhibitor in a bionaïve, moderate PsA phenotype, and the IL-23 inhibitor's potential role in managing patients with PsA.

A Phase 3 Trial of a JAKi in Patients With Giant Cell Arteritis

Save

Listen as coinvestigator and rheumatologist Dr. Andrea Rubbert-Roth reviews this Phase 3 trial of a JAKi in patients with giant cell arteritis. Dr. Rubbert-Roth discusses the latest results, including efficacy and safety outcomes.

Lupus Nephritis

Save

View our six video perspectives on lupus nephritis, including Management of CKD in Lupus Nephritis.

Biomarkers in RA

Save

Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.

Treatment goals for RA: Is it time to transition MOAs?

Save

Rheumatologists Dr. Christina Charles-Schoeman and Dr. Manish Jain discuss their approaches to setting and pursuing treatment goals for patients with poorly controlled RA after TNFis

EXXELERATE: New Thoughts on High RF Titer

Save

Two leading rheumatologists share insights into why RF levels are important to consider when identifying treatment options for patients with RA.

Autoimmune Myositis: The Role of the Laboratory in Diagnosis and Phenotyping

Save

Hear from rheumatologist Stanley J. Naides MD, FACP, FACR, as he details the clinical features of autoimmune myositis, the associated phenotypes and autoantibodies, plus the methodologies and testing options to support a myositis diagnosis.

Minimizing Steroids in Lupus

Save

Minimizing steroid use in patients with SLE. Learn more about when, why, and how to taper steroids and listen to experts, Dr Michelle Petri and Dr Leanna Wise, discuss key data and their clinical perspectives on these topics.

RA Risk Radar: Heart Disease, Infection, and Malignancy

Save

Listen as rheumatologists Dr. Jeffery Curtis and Dr. Jon Giles review comorbidities that can occur as a consequence of uncontrolled, or under-controlled, inflammation in rheumatoid arthritis. In this conversation they share their clinical expertise on a range of topics, including risk assessment, risk management, and the importance of disease control.

Physician Case Reports: Manifestations in Patients with Severe Active GPA/MPA

Save

A review of two physician case reports. These cases are patients who presented with severe active manifestations of granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).

Earlier treatment with biologics to reduce the risk of organ damage in systemic lupus erythematosus (SLE)

Save

Learn about the importance of reducing organ damage and corticosteroid-associated toxicity in SLE, and how biologics may help to change the course of the disease by targeting its underlying mechanisms.

Diagnosis of PMR

Save

Nine perspectives now available: Red Flags in the Diagnosis of PMR; Epidemiology of PMR; Role of the PCP in Diagnosis and Care; Importance of Diagnostic Imaging; ESR/CRP in PMR; PMR Must Rule Outs; Which PMR Patients Should Rheumatologists See?; Is There Hidden GCA?; and PMR Mimics.